EU/3/17/1908: Orphan designation for the treatment of retinitis pigmentosa
Recombinant truncated N-terminal fragment of human lens epithelium-derived growth factor
Table of contents
Overview
On 23 August 2017, orphan designation (EU/3/17/1908) was granted by the European Commission to Dorian Regulatory Affairs BV, the Netherlands, for recombinant truncated N-terminal fragment of human lens epithelium-derived growth factor for the treatment of retinitis pigmentosa.
Key facts
Active substance |
Recombinant truncated N-terminal fragment of human lens epithelium-derived growth factor
|
Medicine name |
-
|
Intended use |
Treatment of retinitis pigmentosa
|
Orphan designation status |
Withdrawn
|
EU designation number |
EU/3/17/1908
|
Date of designation |
23/08/2017
|
Sponsor |
Dorian Regulatory Affairs BV
Soestdijkerstraatweg 7 1213 VP Hilversum The Netherlands Tel. +31 35 622 19 34 Fax +31 35 623 06 59 E-mail: info@dorian.nl |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Update history
Date | Update |
---|---|
August 2022 | Please note that this product was withdrawn from the Union Register of orphan medicinal products in August 2022 on request of the Sponsor. |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: